Last reviewed 2026-04-20 · How we verify

Ultravist 370 (IOPROMIDE)

Ultravist 370 works by accumulating in body fluids and tissues, allowing for enhanced contrast in medical imaging.

Ultravist 370 (Iopromide) is a radiographic contrast agent, a small molecule developed by Bayer Healthcare, which remains under the company's ownership. It is used to enhance the visibility of internal structures during medical imaging procedures. Although its target is unknown, it has been FDA-approved since 1995 for various indications. As an off-patent product, there are currently no generic manufacturers. Key safety considerations include its 2.6-hour half-life.

At a glance

Mechanism of action

ULTRAVIST injection is nonionic, water soluble, tri-iodinated x-ray contrast agent for intravascular administration. Intravascular injection of ULTRAVIST injection opacifies those vessels in the path of flow of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs.

Approved indications

No approved indications tracked.

Boxed warnings

• WARNING: NOT FOR INTRATHECAL USE WARNING: NOT FOR INTRATHECAL USE See full prescribing information for complete boxed warning. Intrathecal administration, even if inadvertent, may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. ULTRAVIST is not approved for intrathecal use. (5.1)

Common side effects

• Headache
• Nausea
• Vasodilatation
• Vomiting
• Back pain
• Urinary urgency
• Chest pain
• Dysgeusia
• Abnormal vision
• Injection site and infusion site reactions
• One or more adverse reactions
• Sensations of warmth

Key clinical trials

• Low-acid Contrast Media for Preventing Post ERCP Pancreatitis
• Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging (NA)
• Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions (NA)
• A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions
• Preoperative Assessment of Pathological Nipple Discharge With Delayed Ductal Imaging of Contrast-enhanced Mammography (NA)
• Multislice CT Angiography of Coronary Bifurcations and Outcomes After Intervention (NA)
• Serum Thyroid Function After Iodinated Contrast Administration
• Short-Term Exposure to Lipophilic Anti-proliferative Drugs Delivered by Angiographic Contrast Media (PHASE1,PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.